Sign in

CIK 0001599298

  • Large accelerated filer

Summit Therapeutics Inc.

Sign in to watch
Ticker
SMMT
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Entity type
Operating
EIN
371979717
Phone
+1 305-203-2034
Business address
601 BRICKELL KEY DRIVE, SUITE 1000, MIAMI, FL, 33131
Former names
Summit Therapeutics plc, Summit Corp plc
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$0
in 0 filings

Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Date Insider Transaction Shares Price Value Owned after
2020-11-23 Powell David Jonathan Chief Scientific Officer Option exercise · Stock Option (right to buy) −6,987 $1.92 $13K 457,699
2020-11-22 Zanganeh Maky Chief Operating Officer Grant or award · Stock Option (right to buy) +2,400,000 3,724,499
2020-11-11 Zanganeh Maky Director Grant or award · Stock Option (right to buy) +200,000 1,321,177
2020-11-11 Zanganeh Maky Director Grant or award · Stock Option (right to buy) +3,323 1,324,500
2020-11-06 DUGGAN ROBERT W Chief Executive Officer Purchase +14,071,856 $3.34 $47.0M 56,296,533
2020-10-04 Graham Camilla Chief Clinical Affairs Officer Grant or award · Stock Option (right to buy) +400,000 $3.34 $1.3M 400,000
2020-10-02 DUGGAN ROBERT W Chief Executive Officer Grant or award · Common Stock +9,730,539 9,730,539

Page 10 of 10 · 187 trades